TY - JOUR T1 - Genomic Epidemiology of SARS-CoV-2 in Esteio, Rio Grande do Sul, Brazil JF - medRxiv DO - 10.1101/2021.01.21.21249906 SP - 2021.01.21.21249906 AU - Vinícius Bonetti Franceschi AU - Gabriel Dickin Caldana AU - Amanda de Menezes Mayer AU - Gabriela Bettella Cybis AU - Carla Andretta Moreira Neves AU - Patrícia Aline Gröhs Ferrareze AU - Meriane Demoliner AU - Paula Rodrigues de Almeida AU - Juliana Schons Gularte AU - Alana Witt Hansen AU - Matheus Nunes Weber AU - Juliane Deise Fleck AU - Ricardo Ariel Zimerman AU - Lívia Kmetzsch AU - Fernando Rosado Spilki AU - Claudia Elizabeth Thompson Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/26/2021.01.21.21249906.abstract N2 - Brazil is the third country most affected by Covid-19 pandemic. In spite of this, viral evolution in municipality resolution is poorly understood in Brazil and it is crucial to understand the epidemiology of viral spread. We identified four main circulating lineages in Esteio (Southern Brazil) and their relationship with global, national and regional lineages using phylogenetics and phylodynamics inferences from 21 SARS-CoV-2 genome sequences. We provided a comprehensive view of viral mutations from a time- and age-representative sampling from May to October 2020, in Esteio (RS, Brazil), highlighting two frequent mutations in Spike glycoprotein (D614G and V1176F), an emergent mutation (E484K) in Spike Receptor Binding Domain (RBD) characteristic of the South African lineage B.1.351, and the adjacent replacement of 2 amino acids in Nucleocapsid phosphoprotein (R203K and G204R). A significant viral diversity was evidenced with the identification of 80 different SNPs. The E484K replacement was found in two genomes (9.5%) from samples obtained in mid-October, which is to our best knowledge the earliest description of E484K harboring SARS-CoV-2 in South Brazil. This mutation identified in a small municipality from the RS state demonstrates that it was probably widely distributed in the Brazilian territory, but went unnoticed so far by the lack of genomic surveillance in Brazil. The introduction of E484K mutants shows temporal correlation with later increases in new cases in our state. Importantly, since it has been associated with immune evasion and enhanced interaction with hACE-2, lineages containing this substitution must be the subject of intense surveillance. Our date demonstrates multiple introductions of the most prevalent lineages (B.1.1.33 and B.1.1.248) and the major role of community transmission in viral spreading and the establishment of Brazilian lineages. This represents an important contribution to the epidemiology of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from Prefeitura Municipal de Esteio (Esteio Mayor Office). Student scholarships were supplied by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brasil (CAPES), Finance Code 001. The funders had no role in the study design, data generation and analysis, decision to publish or the preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Brazilian National Ethics Committee (Comissao Nacional de Etica em Pesquisa, CONEP) under process number 30934020.5.0000.0008. All samples were anonymized before received by the study investigators.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesConsensus genomes have been submitted to the GISAID database under accession numbers EPI_ISL_831471, EPI_ISL_831474, EPI_ISL_831645, EPI_ISL_831646, EPI_ISL_831660, EPI_ISL_831678, EPI_ISL_831681, EPI_ISL_831683, EPI_ISL_831685, EPI_ISL_831688, EPI_ISL_831689, EPI_ISL_831892, EPI_ISL_831898, EPI_ISL_831913, EPI_ISL_831938, EPI_ISL_831939, EPI_ISL_831940, EPI_ISL_832013, EPI_ISL_832012, EPI_ISL_832011, EPI_ISL_832010, EPI_ISL_83209. The publicly available sequences used are acknowledged in the Supplemental File 3. All data is available on the manuscript and supplementary files. ER -